retatrutide type 2 diabetes trial results phase Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people Retatrutide TRANSCEND-T2D-1 topline results are

Previous assumptions held that these medications wouldnt directly affect liver enzymes since GLP-1 receptors arent present in significant quantities on hepatocytes (liver cells)

Journal of Diabetes

Mumbai, as a metropolitan hub, is at the forefront of adopting new wellness trends, and peptide therapy is no exception

Retatrutides safety profile demonstrated tolerable side effects, predominantly gastrointestinal disturbances, underscoring the need for patient guidance and monitoring

Frias et al

They stimulate the production of healthy collagen and hence, there is improvement in skin thickness and elasticity, skin tone, crepiness, lines and wrinkles and hydration